
With the rising prevalence of chronic diseases worldwide, favorable government measures, and the growing adoption of AI in healthcare, demand for innovative drugs and treatments has been rising considerably, boosting the biotech industry’s outlook. Given the industry’s steady growth prospects, investors could buy A-rated biotech stocks Entrada Therapeutics, Inc. (TRDA), Corcept Therapeutics Incorporated (CORT), and Alkermes plc (ALKS) this year.
Growing foothold of personalized medicine and an increasing number of orphan drug formulations are opening new avenues for biotechnology applications and are driving the influx of emerging and innovative biotechnology companies, further boosting the market revenue.